Publications by authors named "K Randle"
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC.
View Article and Find Full Text PDFArticle Synopsis
- The c-TRAK TN trial investigated the use of circulating tumor DNA (ctDNA) surveillance as a method to predict relapse in early-stage triple-negative breast cancer (TNBC) patients after treatment.
- The trial enrolled patients with residual disease post-chemotherapy and involved blood tests every three months for a year to monitor ctDNA levels, with ctDNA+ patients receiving pembrolizumab if indications of recurrence were found.
- Out of 161 patients monitored, 27.3% tested positive for ctDNA within 12 months, but only five were treated with pembrolizumab, and none showed a complete response, highlighting challenges in effectively using ctDNA monitoring for treatment decisions.
Article Synopsis
- The study investigates the effectiveness of ctDNA testing in advanced breast cancer, aimed at avoiding repeat biopsies and helping to select patients for targeted therapies based on their genetic mutations.
- Conducted across 18 UK hospitals, it involved women with advanced breast cancer who had undergone prior treatments, and assessed responses to various mutation-specific treatments aligned with their ctDNA profiles.
- The trial is ongoing, with recruitment completed and primary endpoints focused on measuring response rates, and is registered under several clinical trial databases.
: The prevalence of chronic growth hormone deficiency (GHD) and its association with other hormonal deficiencies was determined in middle-aged patients post-stroke with and without consideration of body mass index (BMI).: Clinical records were reviewed to determine pituitary function at least 3 months post-stroke. Patients with a history of endocrine anomalies were excluded.
View Article and Find Full Text PDF